Cancer patients can learn about new clinical drug treatments. VC004 is the second generation TRK inhibitor . It is a new cancer drug jointly studied by many famous hospitals. If cancer patients have difficulty in treating them, they should not miss the best clinical opportunity!
VC004 inhibits tumor growth through specific cancer targets. In preclinical studies, VC004 has shown higher kinase activity, in vitro cellular activity and in vivo drug-effectiveness activity of , and through research, it was found that new drugs have the second-generation inhibitor attributes of "improving first-generation drug resistance mutations".
cancer new drugs can treat lung cancer of various cancers, liver cancer , gastric cancer , colon cancer, rectal cancer, cecum cancer, pharyngeal cancer, laryngeal cancer, etc. Especially for patients with drug resistance, for patients with cancer resistance, drug resistance is often the same as the sentence of death, but with the continuous research of new drugs, this death curse will also be broken.
new cancer drugs are jointly researched by multiple hospitals, including Cancer Hospital of the Chinese Academy of Medical Sciences, Jiangsu Provincial Hospital of Traditional Chinese Medicine, Tianjin Cancer Hospital, Henan Province Cancer Hospital, Hunan Province Cancer Hospital, Liaoning Province Cancer Hospital, Hubei Province Cancer Hospital, Shaanxi Cancer Hospital , Shanxi Cancer Hospital and many other hospitals!
Many patients are worried about clinical treatment. New cancer drugs are reviewed by the hospital ethics committee and announced by the China National Medical Products Administration. They are new drugs that have been used for clinical practice after multiple reviews. The clinical treatment conditions are harsh:
- is older than 18 years old, and men and women do not limit
- can take care of themselves, and their thinking is clear and
- patients do not have severe hypertension, diabetes , etc.
